{"id":18687,"date":"2023-09-27T12:03:34","date_gmt":"2023-09-27T11:03:34","guid":{"rendered":"https:\/\/psychedelichealth.co.uk\/?p=18687"},"modified":"2023-09-27T12:04:27","modified_gmt":"2023-09-27T11:04:27","slug":"study-dmt-therapy-ssris","status":"publish","type":"post","link":"https:\/\/psychedelichealth.co.uk\/2023\/09\/27\/study-dmt-therapy-ssris\/","title":{"rendered":"Study results suggest improved efficacy of DMT therapy with SSRIs\u00a0"},"content":{"rendered":"

Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company\u2019s native DMT – in patients with Major Depressive Disorder (MDD).<\/b><\/h3>\n

The study investigated the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of a single 27.5 mg intravenous infusion of SPL026, alone or in combination with SSRIs, together with support therapy.<\/p>\n

The company has confirmed that a total of 171\u00a0patients took part in the study, with the test cohort (the SSRI Cohort) consisting of patients currently on a stable treatment course of SSRIs, which have been ineffective in fully relieving their depression symptoms.\u00a0<\/span><\/p>\n